Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics director Christopher Peetz reported equity awards and holdings. On July 15, 2026 he received 4,315 RSUs, each convertible into one share upon vesting on the earlier of June 5, 2027 or immediately before the next annual stockholder meeting, subject to continued service.
He also received stock options for 21,486 and 13,010 shares at an exercise price of $27.78 per share, vesting over time as described and expiring July 15, 2036. An additional 187,500 shares are held indirectly by The Peetz Family Trust, for which he disclaims beneficial ownership beyond his pecuniary interest.
Arcutis Biotherapeutics, Inc. director Christopher Peetz filed an initial ownership report listing 187,500 shares of common stock held indirectly through The Peetz Family Trust dated February 15, 2017. He is a trustee and disclaims beneficial ownership beyond his pecuniary interest.
Arcutis Biotherapeutics director Howard G. Welgus reported multiple Common Stock transactions on July 15, 2026. He sold 4,730 shares at $26.91 per share and exercised stock options to acquire 2,255, 1,019 and 822 shares at exercise prices of $8.63, $7.51 and $6.5223, respectively. Following these trades, he directly owned 37,109 shares of Common Stock. All transactions were effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, with a plan end date of June 15, 2027.
Arcutis Biotherapeutics, Inc. expanded its Board of Directors from nine to ten members and appointed Christopher Peetz as a Class III independent director, effective July 15, 2026, with a term running until the 2029 annual meeting of stockholders, subject to earlier termination events.
Peetz, co‑founder and chief executive officer of Mirum Pharmaceuticals and a veteran biopharmaceutical executive, will receive an initial option to purchase 21,486 shares, a prorated annual equity award valued at about $350,000 (65% stock options and 35% restricted stock units), and a prorated $50,000 cash retainer under Arcutis’ non‑employee director program. Arcutis highlights its commercial-stage immuno‑dermatology focus and its ZORYVE roflumilast franchise, described as the number one prescribed branded topical therapy across atopic dermatitis, seborrheic dermatitis, and plaque psoriasis.
Arcutis Biotherapeutics shareholder Howard Welgus plans to sell up to 4730 shares of common stock through Merrill Lynch on NASDAQ, with an approximate sale date of 07/15/2026 and an aggregate market value of 127284.3. The shares come from restricted stock vesting and stock option exercises totaling 634, 822, 1019 and 2255 shares. The notice also lists prior sales of 7144, 4096 and 635 shares on 05/01/2026, 06/15/2026 and 06/17/2026, respectively.
Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares of common stock in an open-market transaction at a weighted average price of $24.38 per share. After the sale, she directly holds 27,567 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2025.
Arcutis Biotherapeutics director Howard G. Welgus reported option exercises and share sales in the company’s stock. On June 15, 2026, he exercised stock options to acquire a total of 4,096 shares of common stock at exercise prices between $6.5223 and $8.63 per share.
On the same day and on June 17, 2026, he sold a total of 4,731 shares of common stock in open-market transactions at weighted average prices of $24.4093 and $25.67 per share, respectively. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Welgus directly owned 37,743 shares of Arcutis common stock.
Arcutis Biotherapeutics insider reported multiple sales of common stock and a small restricted-stock vesting. Howard Welgus disclosed sales totaling 21,240 shares executed on 04/01/2026, 05/01/2026, and 06/15/2026. The filing also notes a 635-share restricted stock vesting on 06/04/2026.
The three sales list proceeds of $238,800, $164,219.71, and $99,980.49 respectively in the provided lines. The filing is a Form 144 disclosure of these transactions under the issuer name Arcutis Biotherapeutics.
Arcutis Biotherapeutics submitted a Form 144 notice to sell 4,096 shares of Common Stock, with the filing dated 06/15/2026. The filing lists underlying grants described as stock option exercises (counts: 822, 1,019, 2,255) tied to earlier grant dates and shows two recent sales by Howard Welgus of 10,000 and 7,144 shares during April–May 2026.